Hodgkin Disease

• 

  Subject Areas on Research

  • 1982 resident's essay award: the immunologic effects of lymphoid irradiation in human and non-human primates: cellular changes and the potential for renal transplantation. 
  • 5-Fluorouracil in childhood solid tumors. 
  • A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A monoclonal IgM with antibodylike specificity for phospholipids in a patient with lymphoma. 
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. 
  • A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. 
  • A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15? 
  • Acquisition of CD30 and CD15 accompanied with simultaneous loss of all pan-T-cell antigens in a case of histological transformation of mycosis fungoides with involvement of regional lymph node: an immunophenotypic alteration resembling classical Hodgkin lymphoma. 
  • Adult respiratory distress syndrome after limited thoracic radiotherapy. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. 
  • An Epstein-Barr virus-positive classical Hodgkin lymphoma with exclusive sinusoidal growth pattern: An unusual morphologic variant. 
  • An exploratory study of environmental and medical factors potentially related to childhood cancer. 
  • Atypical presentation of pneumococcal pneumonia in a patient undergoing bone marrow transplantation for Hodgkin's disease. 
  • Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. 
  • Bone marrow transplantation. Part II--autologous. 
  • Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma. 
  • Childhood Hodgkin Lymphoma: Think DADA2. 
  • Climate, socioeconomic status and Hodgkin's disease mortality in the United States. 
  • Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. 
  • Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks. 
  • Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. 
  • Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. 
  • Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus. 
  • Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. 
  • Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. 
  • Cryptococcal meningitis with normal cerebrospinal fluid. 
  • Cytomegalovirus retinitis associated with Hodgkin's disease. 
  • Differentiation of radiation fibrosis from recurrent neoplasia: a role for 31P MR spectroscopy? 
  • Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Dynamic assessment of quality of life after autologous bone marrow transplantation. 
  • Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. 
  • Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. 
  • Effects of nitrogen mustard and splenectomy on mouse bone marrow colony formation in vitro. 
  • Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. 
  • Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. 
  • Enlargement of mediastinal masses on simulation films: a radiotherapeutic problem in the management of patients with Hodgkin's disease. 
  • Epidural spinal compression as an initial presentation of Hodgkin lymphoma. 
  • Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. 
  • Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. 
  • Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. 
  • Experts on their own experiences: the rise of patient-reported outcomes in oncology drug trials. 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. 
  • G-CSF and peripheral blood progenitor cells. 
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. 
  • Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. 
  • Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. 
  • HL-A antigenic loss in malignant transformation. 
  • Hair regrowth after cancer therapy. 
  • Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. 
  • Height at diagnosis of malignancies. 
  • High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. 
  • High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. 
  • High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. 
  • High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. 
  • High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. 
  • High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. 
  • Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Hodgkin disease/lymphoma. 
  • Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. 
  • Hodgkin disease: clinical utility of CT in initial staging and treatment. 
  • Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. 
  • Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. 
  • Hodgkin lymphoma, version 2.2015. 
  • Hodgkin lymphoma. 
  • Hodgkin's disease presenting as myelofibrosis. 
  • Hodgkin's disease treated with neck radiation is associated with increased antibody-dependent cellular cytotoxicity against human extraocular muscle cells. 
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. 
  • Hodgkin's lymphoma of the breast. 
  • How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? 
  • Ig-positive lymphocytes in Hodgkin's disease. 
  • Imaging of late complications from mantle field radiation in lymphoma patients. 
  • Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab. 
  • Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes. 
  • Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. 
  • Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidence of anemia in children with solid tumors or Hodgkin disease. 
  • Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Inhibiting inhibitory pathways in human γδ T cells. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interstitial hyperthermia in combination with brachytherapy. 
  • Intra-abdominal desmoid tumor after successful treatment for Hodgkin disease. 
  • Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. 
  • Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. 
  • Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. 
  • Long-term follow-up of Hodgkin's disease trial. 
  • Long-term follow-up of survival in Hodgkin's lymphoma. 
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. 
  • Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases. 
  • Malignant peripheral nerve sheath tumor of the spine after radiation therapy for Hodgkin's lymphoma. 
  • Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. 
  • Mediastinal bulk in Hodgkin disease. Method of measurement versus prognosis. 
  • Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. 
  • Multimodality surgical and hyperbaric management of mandibular osteoradionecrosis. 
  • NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. 
  • Nodular lymphocyte predominant Hodgkin lymphoma at atypical locations may be associated with increased numbers of large cells and a diffuse histologic component. 
  • Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • Patient-reported distress in Hodgkin lymphoma across the survivorship continuum. 
  • Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. 
  • Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. 
  • Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. 
  • Primary intracerebral Hodgkin lymphoma with recurrence. 
  • Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma. 
  • Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. 
  • Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study. 
  • Proton radiotherapy for Hodgkin's disease in the sacrum. 
  • Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. 
  • Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. 
  • Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone. 
  • Radiation-associated valvular heart disease. 
  • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. 
  • Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. 
  • Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. 
  • Results of treatment of stage 3A Hodgkin's disease. 
  • Results of treatment of stage IA and IIA Hodgkin's disease. 
  • Retinopathy and optic neuropathy after transplantation. 
  • Retroperitoneal fibrosis following treatment for Hodgkin's disease. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • Salvage therapy in Hodgkin's lymphoma. 
  • Sarcoma of bone and soft tissue following treatment of Hodgkin's disease. 
  • Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. 
  • Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. 
  • Self-administration of morphine in bone marrow transplant patients reduces drug requirement. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. 
  • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. 
  • Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. 
  • Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. 
  • Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. 
  • Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. 
  • Steroid premedication before i.v. contrast-enhanced CT resulting in resolution of lymphadenopathy. 
  • Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. 
  • Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. 
  • Successful fertilization and pregnancy outcome in in-vitro fertilization using cryopreserved/thawed spermatozoa from patients with malignant diseases. 
  • Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. 
  • The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. 
  • The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). 
  • The biology of human lymphoid malignancies revealed by gene expression profiling. 
  • The cost-benefit ratio of the cure of Hodgkin's disease. 
  • The effect of patient-specific factors on radiation-induced regional lung injury. 
  • The effect of the respiratory cycle on mediastinal and lung dimensions in Hodgkin's disease. Implications for radiotherapy gated to respiration. 
  • The efficacy-toxicity conundrum: breaking the mold. 
  • The pattern of intrathoracic Hodgkin's disease assessed by computed tomography. 
  • The significance of necrotic mediastinal lymph nodes on CT in patients with newly diagnosed Hodgkin disease. 
  • Three months in the symptom life of a teenage girl undergoing treatment for cancer. 
  • Thyroid nodules and survivors of Hodgkin's disease. 
  • Total lymphoid irradiation as an immunosuppressive agent for transplantation and the treatment of 'autoimmune' disease: a review. 
  • Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. 
  • Upper extremity lymphangiography as an aid to treatment planning for stage 1A epitrochlear hodgkin's disease. 
  • Use of amifostine in bone marrow purging. 
  • Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • Virtual reality as a distraction intervention for older children receiving chemotherapy. 
  • Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. 
  • [Bilateral breast cancer after Hodgkin disease. Clinical and pathological characteristics and therapeutic possibilities: an analysis of 13 cases].